For Immediate Release
Chicago, IL – December 17, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Watson Pharmaceuticals, Inc. (WPI), Perrigo Co. (PRGO), Abbot Laboratories (ABT), Merck & Co. Inc. (MRK) and Teva Pharmaceutical Industries (TEVA).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Friday’s Analyst Blog:
An End to Drug Patent Woes?
The US Supreme Court will soon hear a case which will determine whether “pay-for-delay" agreements between drug manufacturers violate anti-trust legislations. These “reverse payment” agreements enable patent holders to pay generic drug manufacturers to delay the launch of generic versions of their drugs. This runs contrary to normal practice, where patent holders sue violators and then seek damages, in some cases through an out of court settlement.
The companies standing to benefit in this case were Watson Pharmaceuticals, Inc. (WPI), Paddock Pharmaceuticals – now owned by Perrigo Co. (PRGO) – and Par Pharmaceuticals, Inc. – which was acquired this year by private equity firm TPG Capital. Solvay Pharmaceuticals Inc, now owned by Abbot Laboratories (ABT), was paying them to delay launch of a competing drug.
These companies received annual payments of between $31 million to $42 million in order to delay launching generic versions of AndroGel until 2015, when Solvay’s patent on the drug would expire. Such an agreement would have helped Solvay maintain annual profits to the tune of $125 million.
The Federal Trade Commission, which is the appellant in the case, has said that 28 such deals concluded last year have cost consumers and taxpayers a minimum of $3.5 billion in synthetically inflated prices.
That pharma giants are resorting to such measures comes as no surprise when one considers the fact that 2012 has seen an industry-wide decline in drug sales. According to Ernst and Young, combined sales of the leading global thirteen drug firms will decline by nearly 4% from around $557 billion in 2011.
Expirations of drug patents are a major factor. A “patent cliff” is characterized by a steep fall in revenues when one or more of the firm’s best-selling products lose their patent protection. As a result, the industry as a whole finished with lower sales for the year compared to 2011.
The good news is that the end of 2012 will also mean an end to the current patent cliff, which has lasted for nearly eighteen months. By next year, the worst will be over.
Meanwhile, despite such conditions, share prices of industry bellwethers like Merck & Co. Inc. (MRK) and Pfizer have risen 25% this year -- nearly twice as much as the increase in the S&P 500. Drug-makers have delivered steady earnings and large dividends, even while taking a hit from patent expirations.
This is because they have spent these trying times reorienting their focus. Historically good at marketing and distribution, pharma companies have spent more time on cost reduction initiatives and have invested in research in a big way. The emphasis on research has resulted in large investments in biotechnology.
According to CLSA, a unit of French bank Credit Agricole, by 2012, six of the top twenty drugs will be biologics. This will probably change the game in favor of patent holders, since it is much tougher to produce “biosimilars,” the generic versions of biologics.
Though generic manufacturers will lose many opportunities as a result, some of them are already readying strategies to cope. Teva Pharmaceutical Industries (TEVA) and Watson Pharmaceuticals have resorted to inorganic growth. Teva acquired Israel-based Cephalon for $6.5 billion last year, while Watson purchased Actavis for $5.6 billion in October this year.
In summary, the loss of patent protection has been a major factor which has propelled changes in the way the industry operates. Companies have radically changed their business models and reoriented their focus in response to the current situation. And by now, the worst is most likely over.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com